Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Lawyers Provide Updates on Biosimilar Litigation (<i>The Center for Biosimilars</i>)

main

12_27 FEATURE Goodwin Lawyers Provide Updates

FEATURE: Goodwin Lawyers Provide Updates on Biosimilar Litigation <i>(The Center for Biosimilars)</i>

Goodwin Lawyers Provide Updates on Biosimilar Litigation (The Center for Biosimilars)

Related Content

$46 Million Veloxis Settlement Yields Record Sunshine Penalty and Insights Into DOJ’s Cross-Agency Data Use

340B Drug Rebate Pilot Program Revised by HRSA

Could States Create Their Own Pathways to Access Experimental Treatments? Montana May Be Testing the Limits of FDA’s Traditional Role

Caremark Settles PBM FTC Action Regarding Reimbursement Practices, Second Major PBM to Settle

US Senate Probes FDA Bureaucracy vs. Innovation

Stronger Together: NORD’s Congressional Briefing on the Heels of FDA’s “Plausible Mechanism” Draft Guidance

Final FY 2026 NDAA Includes BIOSECURE Act Provisions and New Opportunities for Biotech as DOD National Security Priority

CMS Releases MFN Drug Pricing Models for Medicare Parts B and D and Medicaid Amid Trump Administration’s Push for Direct-to-Consumer Strategy

Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

What JPM Tells Us About Healthcare Deals In 2026 (Law360 Healthcare Authority)

Goodwin Releases 2025-26 Update to Annual Biosimilars Guide

Biosecure Makes Annual Defense Bill, with Less 'Bite' for Drugmakers (Endpoints News)

Pharma Execs Reflect on 2025 (Healthcare Brew)

Best Law Firms 2026 Names Goodwin ERISA Litigation Law Firm of the Year and Recognizes 50 Practice Areas

FDA’s New Fast Drug Review Plan Comes with Trade-Offs for Pharma (Bloomberg Law)

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Fourteenth Consecutive Year

Life Sciences

Life Sciences Regulatory & Compliance

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation